No Items In Cart
More recently, issues such as protein aggregation, glass delamination, particles and the need for more precise and complex drug containers has led to an increased awareness and interest in polymer solutions as a preferred alternative to glass when considering new products. Increasing regulatory scrutiny of glass-related issues also has increased awareness of the potential risks to patients and the need to focus on safer solutions.
West recently presented several case studies reflecting the various benefits of Daikyo Crystal Zenith® (CZ) cyclic olefin polymer systems, and the need for a collaborative relationship among all parties involved in the creation of an effective integrated drug delivery system. Specific data comparing CZ with glass, along with examples of how CZ can be applied to the creation of an integrated system like the West SmartDose® electronic patch injector technology platform were also discussed.
Dr. Nicolas Brandes
Business Development Manager, Daikyo CZ, Europe
Daikyo Crystal Zenith® is a registered trademark of Daikyo Seiko, Ltd.
Daikyo Crystal Zenith® technology is licensed from Daikyo Seiko, Ltd.
SmartDose® is a registered trademark of Medimop Medical Projects Ltd., a subsidiary of West Pharmaceutical Services, Inc.
West seeks partners for its SmartDose® injector technology platform. This platform is intended to be used as an integrated system with drug filling and final assembly completed by the pharmaceutical/biotechnology company.